Condition: Myelofibrosis · Primary Myelofibrosis · Secondary Myelofibrosis · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.
This description comes directly from the study's public registry record.
Francesca Palandri, MD, PhD · +390512143044 · francesca.palandri@unibo.it
Always discuss trial participation with your own doctor first.
| Azienda Ospedaliera Annunziata | Cosenza, Calabria, Italy | Recruiting |
| Grande Ospedale Metropolitano "Bianchi Melacrino Morelli" | Reggio Calabria, Calabria, Italy | Recruiting |
| Università degli Studi di Napoli Federico II U.O.C. di Ematologia e Trapianti di midollo | Naples, Campania, Italy | Recruiting |
| IRCCS Policlinico Sant'Orsola | Bologna, Emilia-Romagna, Italy | Recruiting |
| Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. Anna | Ferrara, Emilia-Romagna, Italy | Recruiting |
| Azienda Ospedaliero-Universitaria di Parma | Parma, Emilia-Romagna, Italy | Recruiting |
| AUSL di Piacenza - Palazzine Medicine Specialistiche | Piacenza, Emilia-Romagna, Italy | Recruiting |
| Dipartimento Oncoematologico - AUSL della Romagna | Ravenna, Emilia-Romagna, Italy | Recruiting |
| Ospedale Infermi di Rimini | Rimini, Emilia-Romagna, Italy | Recruiting |
| A.O.U. Integrata di Udine | Udine, Friuli Venezia Giulia, Italy | Recruiting |
| A.O.U. Policlinico Umberto I - Università degli Studi di Roma "La Sapienza" | Rome, Lazio, Italy | Recruiting |
| Ospedale S. Eugenio | Rome, Lazio, Italy | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06516406